Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is used to treat migraine episodes.

Migraine: provides rapid relief of headache pain and associated symptoms during an acute migraine attack. Acute migraine: reduces the severity and duration of migraine when taken at the first sign of an attack. Migraine with aura: alleviates headache and visual disturbances associated with migraine with aura.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Paresthesia: tingling sensations. - Somnolence: drowsiness.

Serious or Rare Side Effects: - Chest pain: possible cardiac discomfort. - Arrhythmia: irregular heart rhythm. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe hypertension: sudden high blood pressure. - Allergic reaction: rash, swelling, breathing difficulty. - Ischemic events: rare stroke or myocardial infarction.

Before using Naramig, consider the following precautions.

Cardiovascular disease: avoid if you have coronary artery disease, angina, or history of myocardial infarction. Uncontrolled hypertension: do not use in patients with severe high blood pressure. Serotonergic drugs: caution when combined with SSRIs, SNRIs, or MAO inhibitors due to risk of serotonin syndrome. Hemiplegic or basilar migraine: contraindicated in these rare migraine subtypes. Elderly patients: use with caution, monitor for increased sensitivity to side effects. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Naratriptan may interact with several medications.

Major Interactions (Avoid): - MAO inhibitors: increase risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects. - Ergot alkaloids: heightened vasoconstriction and cardiovascular risk. - SSRIs/SNRIs: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure lowering. - Oral contraceptives: possible reduced efficacy of migraine relief. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels. - Antihistamines: may augment drowsiness.